MEGIN
  • About us
  • MEG Maps™
    • What is MEG Maps™
    • Book a MEG Maps™ Demo
  • News & Education
    • News
    • MEGIN Spotlights
    • MEGIN Masterclass
    • Abstracts & Studies
  • Patients
  • Find a MEG site
    • Global
    • North America
  • Get in touch
    • Contact us
    • Book a MEG Maps™ Demo
    • MEGIN Community
  • Community
  • China
Select Page
Quantum leap: How hardware and software leaders MEGIN and BESA combined their strengths to streamline MEG analysis

Quantum leap: How hardware and software leaders MEGIN and BESA combined their strengths to streamline MEG analysis

by MEGIN | Jan 20, 2022 | Masterclass - Data Acquisition and Analysis

Presented by...
MEGIN Joins ABHI UK Pavilion Showcasing Strengths of UK HealthTech at Arab Health 2022

MEGIN Joins ABHI UK Pavilion Showcasing Strengths of UK HealthTech at Arab Health 2022

by MEGIN | Jan 18, 2022 | MEGIN News

MEGIN is delighted to be joining the Association of British HealthTech Industries (ABHI) UK Pavilion at Arab Health 2022, which is taking place from 24- 27 January in Dubai. The exhibition – the largest event of its kind in the Middle East – will showcase more than...
MEG utilization in epilepsy

MEG utilization in epilepsy

by MEGIN | Dec 14, 2021 | Masterclass - Clinical MEG

Presented by Elizabeth Davenport and Sasha Alick...
How Magnetoencephalography is Optimising Neurosurgery – By: Professor Stefano Seri MD, FRCP

How Magnetoencephalography is Optimising Neurosurgery – By: Professor Stefano Seri MD, FRCP

by MEGIN | Dec 12, 2021 | MEGIN News

Despite its success in pre-surgical evaluation in localising brain activity, as well as being approved for the pre-surgical evaluation of medically refractory epilepsy, Magnetoencephalography (MEG) is often overlooked by physicians during the referral stage. Although...
Understanding how pre- and post-natal exposures influence brain development using MEG

Understanding how pre- and post-natal exposures influence brain development using MEG

by MEGIN | Nov 30, 2021 | Masterclass - Basic Research

Presented by Dr. Julia...
« Older Entries
Next Entries »

Subscribe to MEGIN Matters

Don't miss the latest MEG insights and MEGIN news - complete the form below to be added to our mailing list and receive MEGIN Matters right in your inbox!

Join Our Mailing List

Home
About us

MEG Maps™
Careers
Contact us
Join Our Mailing List

Insights & education
News
MEGIN Spotlights
MEGIN Masterclass
Abstracts & studies

MEGIN Community

Patients

Find a MEG site
Global
North America

Connect with us
  • Follow
  • Follow
  • Follow

Copyright 2025© – MEGIN
MEGIN’s new platform MEG Maps™ is powered by TRIUX™ neo and MEGreview™, which have 510(k) clearance from the US Food & Drug Administration (FDA) and are under EU MDR Notified body review, i.e. not available for commercial distribution in the EU area. For commercial distribution, please contact your local MEGIN representative. TRIUX™ neo is intended to non-invasively record brain activity, and when interpreted by trained physicians, to help localize these active areas. All other applications are scientific research in nature. Caution: Federal law (USA) restricts this device to sale by or on the order of a physician
.

Subscribe to MEGIN Matters

Don’t miss the latest MEG insights and MEGIN news – complete the form below to be added to our mailing list and receive MEGIN Matters right in your inbox!